Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...
Cancer Therapy Advisor

Sofetabart Mipitecan Gets Breakthrough Tx Status for Platinum-Resistant Ovarian Cancer

Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.
Indianapolis Business Journal

Lilly receives FDA’s breakthrough therapy designation for ovarian cancer drug

Eli Lilly and Co. has received the U.S. Food and Drug Administration’s breakthrough therapy designation for a drug in development to treat certain ovarian cancer patients. The Indianapolis-based ...
Science Daily

Breakthrough research extends hope for gastric cancer patients with peritoneal metasis

New study and promising results from the first clinical trial in patients provide novel insights and new hope for one of the deadliest of cancers. Gastric cancer remains a formidable adversary, ...

Eli Lilly Gets FDA Breakthrough Designation for Ovarian Cancer Drug

Eli Lilly has won U.S. Food and Drug Administration breakthrough -therapy designation for its sofetabart mipitecan drug candidate for certain patients with ovarian cancer.
Becker's Hospital Review

FDA approves new drug for ovarian, fallopian tube and peritoneal cancer

Zejula can now be used as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk after ...

I Was 21 When My Doctors Told Me I Had A Year To Live. What Happened Next Left Them Stunned.

"The prognosis was so poor that the hospital called in grief counselors to speak with my family and help prepare them." ...